Aurinia Pharmaceuticals (NASDAQ: AUPH) — Perfil da empresa, notícias e dados financeiros
Aurinia Pharmaceuticals focuses on therapies for autoimmune diseases, particularly lupus nephritis, advancing patient care through innovation.
Aurinia Pharmaceuticals
Aurinia Pharmaceuticals (NASDAQ:AUPH) specializes in the development and commercialization of therapies aimed at treating targeted patient populations suffering from serious diseases with a high unmet medical need. Its primary focus is on autoimmune diseases, particularly in the realm of nephrology and autoimmunity. A key project for Aurinia is its innovative drug, voclosporin, designed specifically for the treatment of lupus nephritis, a severe and potentially life-threatening condition. The objective of Aurinia is to achieve breakthroughs in patient care by advancing these treatments through rigorous clinical trials and regulatory pathways, aiming to bring new hope and therapeutic options to patients and healthcare providers worldwide.
Resumo
Operações
Produtos e/ou serviços de Aurinia Pharmaceuticals
- Lupkynis (voclosporin), an FDA-approved treatment for adults with active lupus nephritis.
- Voclosporin oral solution, under investigation for use in pediatric patients with lupus nephritis.
- Ocular formulation of voclosporin, aimed at treating dry eye syndrome.
- Research programs focusing on the applications of voclosporin in other autoimmune diseases.
- Partnerships for the commercialization and distribution of Lupkynis outside of the United States.
- Patient support and assistance programs designed to improve access to treatments for lupus nephritis.
equipe executiva do Aurinia Pharmaceuticals
- Kevin C. TangChairman & CEO
- Stephen P. RobertsonChief Legal Officer, Corporate Secretary & Chief Compliance Officer
- Peter S. GreenleafConsultant
- Michael S. HearneChief Financial Officer
- Ryan ColeChief Operating Officer
- Thomas WeiChief Scientific Officer
- Stewart M. KrollChief Development Officer
Principais indicadores financeiros
Resultados divulgados pela Aurinia Pharmaceuticals, em USD.
- Cap. de mercado
- 2,3 bi
- Receita (TTM)
- 311,5 mi
- P/L
- 7.6
- LPA (diluído, TTM)
- 2.3
- Dividend yield
- —
- Margem de lucro
- 100.8%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 283,1 mi | 104,9 mi | 287,2 mi | |
| 235,1 mi | -4,7 mi | 5,8 mi | |
| 175,5 mi | -91,7 mi | -78 mi | |
| 134 mi | -111,5 mi | -108,2 mi |